Coherus Oncology, Inc. CHRS

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 ("PD-1") inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma ("NPC") and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations. On May 29, 2025, we changed our corporate name from "Coherus BioSciences, Inc." to "Coherus Oncology, Inc." to better align with our exclusive focus on proprietary innovative immuno-oncology medicines following the completion of the recent divestitures of our biosimilar businesses.

Last close 1.01 2026-10-23
Market cap $156.0M 2026-06-30 share count
52-week range 0.94 - 2.62

Valuation FY2025 figures against the last close

P/S3.7x
P/E0.7x
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS1.43

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $42.2M$26.4M$1.2M$211.0M$326.6M$475.8M$356.1M$0$1.6M$189.5M
Cost of revenue $13.8M$8.7M$438.0K$70.1M$57.6M$37.7M$17.1M———
Gross profit $28.4M$17.7M$780.0K$141.0M$269.0M$438.2M$339.0M———
R&D $108.9M$91.8M$96.1M$199.4M$363.1M$142.8M$94.2M$110.2M$162.4M$254.4M
SG&A $100.6M$125.5M$120.5M$198.5M$169.7M$139.1M$137.0M$94.2M$71.3M$51.6M
Total operating expenses $223.3M$226.0M$217.0M$467.9M$590.4M$319.5M$248.3M$204.4M$233.7M$306.0M
Operating income -$181.1M-$199.7M-$215.8M-$256.9M-$263.9M$156.3M$107.8M-$204.4M-$232.1M-$115.9M
Interest expense $9.0M$10.7M$11.1M$32.5M$23.0M$21.2M$17.6M$9.7M$9.6M$8.0M
Pre-tax income -$183.1M-$215.4M-$222.1M-$291.8M-$287.1M$135.7M$92.8M-$209.4M-$238.3M-$127.3M
Income tax $0$0$380.0K$0$0$3.5M$2.9M$0$0$0
Net income $168.0M$28.5M-$237.9M-$291.8M-$287.1M$132.2M$89.8M-$209.3M-$238.2M-$127.3M
EPS, basic 1.430.25-2.53-3.76-3.811.851.29-3.22-4.48—
EPS, diluted 1.430.25-2.53-3.76-3.811.621.23-3.22-4.48-3.04
Shares, diluted (wtd. avg.) 117.1M114.6M94.2M77.6M75.4M83.5M73.2M65.0M53.1M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $88.9M$126.0M$103.3M$63.5M$417.2M$541.2M$177.7M$72.4M$127.8M$125.8M
Short-term investments $83.2M—$14.9M$128.1M——————
Receivables $17.8M$111.3M$260.5M$110.0M$123.0M$157.0M$142.0M$0—$1.9M
Inventory $3.2M$4.2M$62.6M$38.8M$37.6M$44.2M$9.8M$1.7M——
Total current assets $206.7M$341.6M$475.6M$381.2M$602.3M$767.5M$343.0M$84.4M$145.5M$161.5M
Property, plant and equipment $1.3M$2.6M$5.1M$8.8M$7.8M$10.1M$5.8M$6.7M$12.8M$10.8M
Goodwill ——$943.0K$943.0K$900.0K$943.0K$943.0K$943.0K$943.0K$943.0K
Other intangibles $20.0M$24.8M$41.9M$5.9M$3.6M$2.6M$2.6M$2.6M$2.6M$2.6M
Total assets $258.3M$448.5M$629.6M$480.8M$679.3M$841.6M$408.9M$99.5M$162.6M$178.5M
Accounts payable $9.9M$28.5M$35.2M$11.5M$16.2M$15.2M$26.0M$15.3M$15.5M$19.7M
Total current liabilities $140.4M$283.0M$331.8M$138.7M$165.3M$145.7M$115.0M$33.3M$28.4M$56.4M
Total liabilities $197.3M$580.5M$823.0M$618.3M$581.6M$560.7M$303.7M$138.1M$132.1M$159.1M
Retained earnings -$1.38B-$1.55B-$1.58B-$1.34B-$1.05B-$762.8M-$895.0M-$984.8M-$775.5M-$537.3M
Total equity $61.0M-$132.0M-$193.4M-$137.4M$97.7M$281.0M$105.2M-$38.6M$30.5M$19.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$138.5M-$20.4M-$174.9M-$241.1M-$37.4M$154.1M$28.4M-$159.3M-$200.3M-$252.5M
Depreciation and amortisation $1.3M$1.6M$1.8M$3.6M$3.5M—————
Stock-based compensation $17.0M$27.8M$43.1M$50.7M$51.4M$38.2M$33.6M$34.8M$33.4M$27.4M
Capital expenditure ——$286.0K$2.0M$1.3M$7.2M$1.8M$789.0K$4.6M$6.5M
Investing cash flow $375.1M$230.3M$144.6M-$166.8M-$138.4M-$14.4M-$12.7M-$1.2M-$4.4M-$6.5M
Financing cash flow -$273.7M-$187.0M$69.6M$54.3M$51.9M$223.9M$89.4M$105.4M$206.8M$226.2M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-045251.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -400M -200M 0 200M 400M 600M Revenue, FY2016: 189.5M Net income, FY2016: -127.3M Revenue, FY2017: 1.6M Net income, FY2017: -238.2M Revenue, FY2018: 0 Net income, FY2018: -209.3M Revenue, FY2019: 356.1M Gross profit, FY2019: 339M Net income, FY2019: 89.8M Revenue, FY2020: 475.8M Gross profit, FY2020: 438.2M Net income, FY2020: 132.2M Revenue, FY2021: 326.6M Gross profit, FY2021: 269M Net income, FY2021: -287.1M Revenue, FY2022: 211M Gross profit, FY2022: 141M Net income, FY2022: -291.8M Revenue, FY2023: 1.2M Gross profit, FY2023: 780K Net income, FY2023: -237.9M Revenue, FY2024: 26.4M Gross profit, FY2024: 17.7M Net income, FY2024: 28.5M Revenue, FY2025: 42.2M Gross profit, FY2025: 28.4M Net income, FY2025: 168M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $189.5M $1.6M $0 $356.1M $475.8M $326.6M $211.0M $1.2M $26.4M $42.2M
Gross profit — — — $339.0M $438.2M $269.0M $141.0M $780.0K $17.7M $28.4M
Net income -$127.3M -$238.2M -$209.3M $89.8M $132.2M -$287.1M -$291.8M -$237.9M $28.5M $168.0M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%